A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC)

被引：2
|
作者：
Clayton, Ravinder
Heng, Daniel Yick Chin
Wu, Jackson S. Y.
Zielinski, Rob
North, Scott A.
Emmenegger, Urban
Hotte, Sebastien J.
Al-Shamsi, Humaid Obaid
Chen, Leo
Eigl, Bernhard J.
机构：
[1] Tom Baker Canc Clin, Calgary, AB, Canada
[2] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada
[5] Juravinski Canc Ctr, Hamilton, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.113
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
113
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
    Chi, Kim N.
    Rathkopf, Dana
    Smith, Matthew R.
    Efstathiou, Eleni
    Attard, Gerhardt
    Olmos, David
    Lee, Ji Youl
    Small, Eric J.
    Gomes, Andrea J. Pereira De Santana
    Roubaud, Guilhem
    Saad, Marniza
    Zurawski, Bogdan
    Sakalo, Valerii
    Mason, Gary E.
    Francis, Peter
    Ms, George Wang
    Wu, Daphne
    Diorio, Brooke
    Lopez-Gitlitz, Angela
    Sandhu, Shahneen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3339 - +
  • [42] Erratum to Abiraterone acetate: in metastatic castration-resistant prostate cancer
    L. P. H. Yang
    Drugs, 2012, 72 (2) : 192 - 192
  • [43] Abiraterone Acetate (AA) in pre- and post-docetaxel (DX) metastatic castration resistant prostate cancer (mCRPC): a monoinstitutional experience focused on cardiovascular (CV) events
    Cavo, A.
    Rubagotti, A.
    Zanardi, E.
    Fabbroni, C.
    Zinoli, L.
    Arboscello, E.
    Bellodi, A.
    Spallarossa, P.
    Boccardo, F.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2017, 47 : 77 - 77
  • [44] Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2011, 53 (1370): : 63 - 64
  • [45] The use of abiraterone acetate in severely healed patients with metastatic prostate cancer resistant to castration
    Zolnierek, Jakub
    ONCOLOGY IN CLINICAL PRACTICE, 2014, 10 : B11 - B15
  • [46] Abiraterone acetate for castration resistant prostate cancer
    Shah, Shreya
    Ryan, Charles
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (04) : 563 - 570
  • [47] Novel predictive markers of PSA response to abiraterone acetate in men with metastatic castration-resistant-prostate-cancer (mCRPC)
    Leibowitz-Amit, Raya
    Templeton, Arnoud J.
    Atenafu, Eshetu G.
    Vera-Badillo, Francisco Emilio
    Chllamma, Muralidharan
    Solow, Henry L.
    Knox, Jennifer J.
    Tannock, Ian
    Sridhar, Srikala S.
    Joshua, Anthony Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [48] Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.
    Flaig, Thomas W.
    Smith, Matthew R.
    Saad, Fred
    Rathkopf, Dana E.
    Mulders, Peter F. A.
    Small, Eric Jay
    Shore, Neal D.
    Fizazi, Karim
    De Porre, Peter
    Kheoh, Thian
    Li, Jinhui
    Todd, Mary Beth
    Griffin, Thomas W.
    Ryan, Charles J.
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [49] An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
    Efstathiou, Eleni
    Deshpande, Hari
    George, Daniel
    Joshua, Anthony M.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Londhe, Anil
    Todd, Mary
    Molina, Arturo
    CANCER RESEARCH, 2014, 74 (19)
  • [50] Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
    Boegemann, Martin
    Hatzinger, Martin
    Hercher, Dirko
    Matus, Geoffrey
    Everaert, Els Grieta
    Dopchie, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345